Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, women's health and more. And our CME library is continuously growing, every quarter.
Personalized Obesity Management: A Comprehensive Approach
Personalized Obesity Management: A Comprehensive Approach
Breaking the Bias: Addressing Stigma in Obesity Care
Breaking the Bias: Addressing Stigma in Obesity Care
The Power of Shared Decision-Making in Obesity Care
The Power of Shared Decision-Making in Obesity Care
Pulmonary Hypertension: Diagnosis, Management, and Updates – Chairperson’s Perspective
Pulmonary Hypertension: Diagnosis, Management, and Updates – Chairperson’s Perspective
Pharmacotherapy in Obesity: Current and Emerging Options
Pharmacotherapy in Obesity: Current and Emerging Options
The Power of Teamwork: Multidisciplinary Obesity Care
The Power of Teamwork: Multidisciplinary Obesity Care
Recent Guidelines Updates: Implications to Practice
Recent Guidelines Updates: Implications to Practice
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Biomarker-Directed Approaches for Frontline Treatment of Advanced Gastric/GEJ Cancers: The Evidence
Expert Viewpoint: Optimizing Breast Cancer Treatment
Expert Viewpoint: Optimizing Breast Cancer Treatment
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Emerging Directions in Biomarker-Directed Therapy for GI Malignancies
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
Adjuvant Treatments for HR+/HER2- EBC: The Role of CDK4/6 and PARP Inhibitors
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of HER2-Directed Therapy for Second-Line Treatment of HER2+ Metastatic Breast Cancer
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
The Role of Biomarker-Driven Therapies in the Second-Line Treatment of Advanced Gastric/GEJ Cancers: What Do the Data Say?
